JP2024520049A - 敗血症のエンドタイプおよび/または重症度の診断 - Google Patents

敗血症のエンドタイプおよび/または重症度の診断 Download PDF

Info

Publication number
JP2024520049A
JP2024520049A JP2023573024A JP2023573024A JP2024520049A JP 2024520049 A JP2024520049 A JP 2024520049A JP 2023573024 A JP2023573024 A JP 2023573024A JP 2023573024 A JP2023573024 A JP 2023573024A JP 2024520049 A JP2024520049 A JP 2024520049A
Authority
JP
Japan
Prior art keywords
endotype
signature
riok3
fech
lgals3bp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023573024A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024520049A5 (enExample
Inventor
イー. ハンコック、ロバート
バゲラ、アルジュン
フロウエ、ガブリエラ コーエン
Original Assignee
ザ ユニヴァーシティ オブ ブリティッシュ コロンビア
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ ユニヴァーシティ オブ ブリティッシュ コロンビア filed Critical ザ ユニヴァーシティ オブ ブリティッシュ コロンビア
Publication of JP2024520049A publication Critical patent/JP2024520049A/ja
Publication of JP2024520049A5 publication Critical patent/JP2024520049A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6809—Methods for determination or identification of nucleic acids involving differential detection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/686—Polymerase chain reaction [PCR]
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B30/00—Methods of screening libraries
    • C40B30/06—Methods of screening libraries by measuring effects on living organisms, tissues or cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/26—Infectious diseases, e.g. generalised sepsis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Pathology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Theoretical Computer Science (AREA)
  • General Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Evolutionary Biology (AREA)
  • Medical Informatics (AREA)
JP2023573024A 2021-05-25 2022-05-25 敗血症のエンドタイプおよび/または重症度の診断 Pending JP2024520049A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163192746P 2021-05-25 2021-05-25
US63/192,746 2021-05-25
PCT/CA2022/050831 WO2022246553A1 (en) 2021-05-25 2022-05-25 Diagnostic for sepsis endotypes and/or severity

Publications (2)

Publication Number Publication Date
JP2024520049A true JP2024520049A (ja) 2024-05-21
JP2024520049A5 JP2024520049A5 (enExample) 2025-06-10

Family

ID=84229117

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023573024A Pending JP2024520049A (ja) 2021-05-25 2022-05-25 敗血症のエンドタイプおよび/または重症度の診断

Country Status (7)

Country Link
US (1) US20240254557A1 (enExample)
EP (1) EP4352250A4 (enExample)
JP (1) JP2024520049A (enExample)
CN (1) CN117751195A (enExample)
AU (1) AU2022283025A1 (enExample)
CA (1) CA3221576A1 (enExample)
WO (1) WO2022246553A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024148050A2 (en) * 2023-01-04 2024-07-11 Ampel Biosolutions, Llc Longitudinal gene expression analysis of inflammatory skin diseases
EP4766855A1 (en) * 2023-08-22 2026-07-01 Ramot at Tel-Aviv University Ltd. SYSTEMIC RESISTANCE AND INFLAMMATION MARKERS AND THEIR USES
WO2025090733A1 (en) * 2023-10-27 2025-05-01 Sanofi Identifying disease subtypes
CN118389664A (zh) * 2024-04-24 2024-07-26 南方医科大学深圳医院 区分正常患者和脓毒症患者的基因组合物、脓毒症和感染性休克的预测模型的构建方法
CN118621011B (zh) * 2024-06-18 2025-08-29 广东医科大学附属医院 circNfix作为生物标志物在检测、诊断或预后脓毒症急性肾损伤中的应用
CN120939040A (zh) * 2025-10-20 2025-11-14 四川省医学科学院·四川省人民医院 GYG1 siRNA在制备治疗脓毒症的药物中的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018146162A1 (en) * 2017-02-07 2018-08-16 Academisch Medisch Centrum Molecular biomarker for prognosis of sepsis patients
JP2021514620A (ja) * 2018-02-27 2021-06-17 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 敗血症のサブタイプを特定するための堅牢な分類子

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050196817A1 (en) 2004-01-20 2005-09-08 Molecular Staging Inc. Biomarkers for sepsis
JP2008538007A (ja) 2005-04-15 2008-10-02 ベクトン,ディッキンソン アンド カンパニー 敗血症の診断
DE102005050933A1 (de) * 2005-10-21 2007-04-26 Justus-Liebig-Universität Giessen Erfindung betreffend Expressionsprofile zur Vorhersage von septischen Zuständen
US20110076685A1 (en) 2009-09-23 2011-03-31 Sirs-Lab Gmbh Method for in vitro detection and differentiation of pathophysiological conditions
US20110312521A1 (en) 2010-06-17 2011-12-22 Baylor Research Institute Genomic Transcriptional Analysis as a Tool for Identification of Pathogenic Diseases
EP2834638B1 (en) 2012-04-02 2020-02-12 Astute Medical, Inc. Methods for diagnosis and prognosis of sepsis
EP3013985A4 (en) 2013-06-28 2017-07-19 Acumen Research Laboratories Pte. Ltd. Sepsis biomarkers and uses thereof
WO2015117204A1 (en) * 2014-02-06 2015-08-13 Immunexpress Pty Ltd Biomarker signature method, and apparatus and kits therefor
CA2942577A1 (en) 2014-03-14 2015-09-17 Robert E. W. Hancock Diagnostic for sepsis
CN107532214B (zh) 2015-03-12 2021-08-31 斯坦福大学托管董事会 用于败血症诊断的方法
GB201518597D0 (en) * 2015-10-20 2015-12-02 Univ Liverpool Detection of bacterial infection
US11104953B2 (en) * 2016-05-13 2021-08-31 Children's Hospital Medical Center Septic shock endotyping strategy and mortality risk for clinical application
KR101929772B1 (ko) * 2016-11-02 2018-12-17 연세대학교 산학협력단 패혈증 진단을 위한 정보를 제공하는 방법 및 이를 이용한 키트
US20210388443A1 (en) * 2018-11-05 2021-12-16 Institute For Systems Biology Sepsis biomarker panels and methods of use

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018146162A1 (en) * 2017-02-07 2018-08-16 Academisch Medisch Centrum Molecular biomarker for prognosis of sepsis patients
JP2021514620A (ja) * 2018-02-27 2021-06-17 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 敗血症のサブタイプを特定するための堅牢な分類子

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
感染症学雑誌, vol. 92, no. 1, JPN6026018786, 2018, pages 10 - 45, ISSN: 0005862469 *

Also Published As

Publication number Publication date
AU2022283025A1 (en) 2024-01-18
EP4352250A4 (en) 2026-07-01
CA3221576A1 (en) 2022-12-01
US20240254557A1 (en) 2024-08-01
CN117751195A (zh) 2024-03-22
EP4352250A1 (en) 2024-04-17
WO2022246553A1 (en) 2022-12-01

Similar Documents

Publication Publication Date Title
US12473597B2 (en) Methods and systems for processing a nucleic acid sample
AU2020201564B2 (en) Diagnostic for sepsis
EP4352250A1 (en) Diagnostic for sepsis endotypes and/or severity
Rodriguez et al. Viral genomic, metagenomic and human transcriptomic characterization and prediction of the clinical forms of COVID-19
US11091809B2 (en) Molecular diagnostic test for cancer
US11299785B2 (en) Septic shock endotyping strategy and mortality risk for clinical application
US20140342924A1 (en) Molecular Diagnostic Test for Cancer
AU2015213486A1 (en) Biomarker signature method, and apparatus and kits therefor
AU2012261820A1 (en) Molecular diagnostic test for cancer
US20240309469A1 (en) Methods to detect and treat a fungal infection
US20170088902A1 (en) Expression profiling for cancers treated with anti-angiogenic therapy
Daniel et al. Role of CXCL12/CXCR4 pathway and miRNA expression profiles on polymorphonuclear mobilization in COVID-19 patients
HK1237382B (en) Diagnostic for sepsis
HK1237382A1 (en) Diagnostic for sepsis

Legal Events

Date Code Title Description
RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20240311

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20240311

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250523

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250523

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250530

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260519